Key result
Lymphoma linked to ~59% higher mortality after PCI, but not in propensity-matched analysis.
Why the study?
Patients with a history of lymphoma may develop significant CAD treated by PCI, yet long-term outcomes are not well characterized.
Does a history of or active lymphoma increase long-term mortality and major adverse cardiac events in patients undergoing percutaneous coronary intervention compared to non-cancer controls?
Cohort (n=11,953)
No
Does a history of or active lymphoma increase long-term mortality and major adverse cardiac events in patients undergoing percutaneous coronary intervention compared to non-cancer controls?
Patients with past or active lymphoma undergoing PCI have similar long-term survival and MACE rates compared to propensity-matched non-cancer controls.
Answers are grounded in this paper and cite their sources.
Lymphoma history shows no independent link to post-PCI mortality or MACE after matching; hypothesis-generating and should not yet change practice.
Background: Patients with a history of lymphoma may develop significant coronary artery disease (CAD), which may be treated by percutaneous coronary intervention (PCI), yet long term outcomes are not well characterized. Methods: We reviewed patients with a history of lymphoma undergoing PCI from our institutional PCI database and compared characteristics and outcomes to a cohort without cancer. Long-term mortality and major adverse cardiac events (MACE) (cardiac death, myocardial infarction (MI), target vessel revascularization (TVR)) were assessed. Results: Of the 11,953 patients identified, 83 (0.7%) had past or current lymphoma. Most had Diffuse large B-cell lymphoma (DLBCL) (n=23; 28.8%) or Hodgkin’s Lymphoma (HL) (n=22; 27.%), and 31 (37.3%) presented with acute coronary syndrome. Lymphoma patients, as compared to non-lymphoma patients, were similar with respect to age, sex, hypertension, diabetes, hyperlipidemia, prior MI, and prior PCI (all p=ns). The 1, 3, and 5-year survival rates were 90.5%, 69.5 %, and 52.5% in lymphoma patients as compared to 88.0%, 77.1%, and 66.7% in propensity matched non-lymphoma controls. Lymphoma was an independent predictor of mortality (OR 1.59; 95% CI 1.07-2.36, p=0.02) after multivariable adjustment. In propensity matched analysis over a median follow up of 4.2 years (IQR 1.28, 7.73), lymphoma was not independently associated with worse survival or MACE. Conclusions: Among patients with CAD undergoing PCI, <1% had previous or active lymphoma. Although lymphoma may appear predictive of mortality in regression models with multivariable adjustment, mortality and MACE rates are similar to propensity matched controls.
No takes yet. Share an insight, caveat, or question.
Reeves et al. (2026) conducted a cohort in Coronary artery disease undergoing percutaneous coronary intervention (with vs. without history of lymphoma) (n=11,953). History of lymphoma (past or current) vs. Propensity-matched controls without cancer was evaluated on Long-term mortality (5-year survival) and major adverse cardiac events (cardiac death, myocardial infarction, target vessel revascularization) (OR 1.59, 95% CI 1.07-2.36, p=0.02). Lymphoma predicted mortality on multivariable adjustment (OR 1.59; 95% CI 1.07-2.36; p=0.02), but was not associated with worse survival or MACE in propensity-matched analysis.
Synapse has enriched 10 related papers. Consider them for comparative context: